Abstracts tagged "Disease Activity"

Abstract Number: 2983 • 2018 ACR/ARHP Annual Meeting
The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Nathalie Carrier¹, Sophie Roux², Ariel Masetto², Artur J deBrum Fernandes³, Patrick Liang⁴, Meryem Maoui⁵ and Gilles Boire⁴, ¹Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Bristol-Myers Squibb Canada., St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution of baseline demographic, clinical, serological and genetic characteristics of patients with incident RA over 20 years. Methods: Since July 1998,…
Abstract Number: 324 • 2018 ACR/ARHP Annual Meeting
Three Health It Interventions Increased Documentation of RA Disease Activity Scores in an Academic Rheumatology Clinic: Results from an Interrupted Time Series Study
Julie Gandrup^1,2, Jing Li², Zara Izadi³, Milena Gianfrancesco², Torkell Ellingsen⁴, Jinoos Yazdany² and Gabriela Schmajuk^5,6, ¹Rheumatology, Odense University Hospital, Odense, Denmark, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁵San Francisco VA Medical Center, San Francisco, CA, ⁶Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA
Background/Purpose: Regular assessment of disease activity is a fundamental part of high quality RA care. Customization of electronic health records (EHRs) can facilitate the systematic…
Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1643 • 2018 ACR/ARHP Annual Meeting
Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
Ana-Maria Orbai¹, Klaus Krüger², Frank Behrens³, Uta Kiltz⁴, Benoit Guerette⁵, Lillian Mellars⁵, Michele Brunori⁵ and Jürgen Wollenhaupt⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Centre of Rheumatology, Munich, Germany, ³Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: We examined clinical correlations between disease activity, as measured with the Clinical Disease Activity for PsA (cDAPSA) components and PsA life impact/health-related quality of…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Maria Rydholm^1,2, Ingegerd Wikström^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…
Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Jens Rathmann¹, David Jayne², Goran Jönsson³, Mårten Segelmark⁴, Jan-Åke Nilsson⁵ and Aladdin Mohammad², ¹Rheumatology, Skanes University Hospital, Lund, Lund, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…
Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Vibeke Norvang^1,2, Gina Hetland Brinkmann^1,3, Joseph Sexton¹, Anna-Birgitte Aga¹, Siri Lillegraven¹, Till Uhlig^1,2, Tore Kvien^1,2, Maria Dahl Mjaavatten¹ and Espen A. Haavardsholm^1,2, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital, Grålum, Norway
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…
Abstract Number: 327 • 2018 ACR/ARHP Annual Meeting
The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study
Vivian P. Bykerk¹, Orit Schieir², Marie-France Valois³, Edward C. Keystone⁴, Gilles Boire⁵, Janet E. Pope⁶, Diane Tin⁷, Carol Hitchon⁸, Carter Thorne⁹, Susan J. Bartlett¹⁰ and Boulos Haraoui¹¹, ¹Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto, Newmarket, ON, Canada, ¹⁰Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada
Background/Purpose: The patient global assessment (PtGA) is a core domain used in RA composite disease activity (CDA) measures for trials and treat-2-target paradigms. The PtGA…
Abstract Number: 632 • 2018 ACR/ARHP Annual Meeting
Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Clémence Gorlier¹, Laure Gossec², Deborah Puyraimond-Zemmour¹, Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Ana-Maria Orbai²², ¹Sorbonne Université, PARIS, France, ²Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Rheumatology, Université Paris Diderot, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Treatments targets in psoriatic arthritis (PsA) are remission (REM) or Low Disease Activity (LDA) which are usually defined based on objective disease activity but…
Abstract Number: 1458 • 2018 ACR/ARHP Annual Meeting
Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry
Sytske Anne Bergstra¹, Maura Couto², Nimmisha Govind³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, Elizabeth Murphy⁶, Tom W.J. Huizinga¹ and Cornelia F. Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Hospital Sao Teotónio, Viseu, Portugal, Viseu, Portugal, ³University of the Witwatersrand, Johannesburg, South Africa, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶University Hospital Wishaw, Scotland, Wishaw, United Kingdom
Background/Purpose: Despite efforts to predict treatment response, treatment of rheumatoid arthritis (RA) patients remains mostly a case of trial and error. Previous research, mostly in…
Abstract Number: 1665 • 2018 ACR/ARHP Annual Meeting
Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
Daniel Toro¹, Jordi Martorell-Marugán², Daniel Goldman³, Michelle Petri⁴, Pedro Carmona Sanz⁵ and Marta Alarcón-Riquelme^6,7, ¹Bioinformatics and Medical Genomics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Ganada, Spain, ²Bioinformatics Unit, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁶Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain
Background/Purpose: The highly heterogeneous clinical presentation of lupus is characterized by the unpredictable appearance of flares of disease activity and important organ damage. Attempts to…
Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Elena Nikiphorou¹, Sam Norton², Adam Young³, Lewis Carpenter², Josh Dixey⁴, David Walsh⁵ and Patrick Kiely⁶, ¹Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, ²Academic Rheumatology, King's College London, London, United Kingdom, ³University of Hertfordshire, Hertford, United Kingdom, ⁴Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁶Rheumatology Dept, St Georges Hospital, London, Great Britain
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Ayako Kubota¹, Toru Suguro¹, Arata Nakajima², Masato Sonobe³ and Kazuaki Tsuchiya¹, ¹Toho University Omori Medical Center, Tokyo, Japan, ²Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ³Toho University Sakura Medical Center, Chiba, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].